P-gp overexpression in cancer cells decreases chemotherapeutic accumulation and leads to resistance to a variety of currently available anti-cancer drugs, including vinca alkaloids (vinblastine), taxanes (paclitaxel), and anthracyclines (daunorubicin). The gene discussed is PGP; the disease is cancer.